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Abstract
Active myofascial trigger points (MTrPs) have been found to contribute to chronic tension-type
headache and migraine. The purpose of this case series was to examine if active trigger points
(TrPs) provoking cluster-type referred pain could be found in cluster headache patients and, if so,
to evaluate the effectiveness of active TrPs anaesthetic injections both in the acute and preventive
headache's treatment. Twelve patients, 4 experiencing episodic and 8 chronic cluster headache,
were studied. TrPs were found in all of them. Abortive infiltrations could be done in 2 episodic and
4 chronic patients, and preemptive infiltrations could be done in 2 episodic and 5 chronic patients,
both kind of interventions being successful in 5 (83.3%) and in 6 (85.7%) of the cases respectively.
When combined with prophylactic drug therapy, injections were associated with significant
improvement in 7 of the 8 chronic cluster patients. Our data suggest that peripheral sensitization
may play a role in cluster headache pathophysiology and that first neuron afferent blockade can be
useful in cluster headache management.
Introduction
Although many advances have been made concerning the
pathophysiology of cluster headache, the process is still
only partially understood [1]. Hypothalamic dysfunction
and subsequent activation of the trigeminovascular sys-
tem and the cranial parasympathetic system seem to play
a significant role [2]. However, other factors may also play
a relevant role in the generation and/or perpetuation of
cluster pain.
Referred pain arising from myofascial structures has been
shown to be involved in many different disorders, mostly
of musculoskeletal origin, as it is the case of myofascial
pain syndrome [3] but also of visceral origin such as renal
calculi, biliar calculi, dysmenorrhea, or myocardial infarc-
tion among others [4-6]. Active myofascial trigger points
(MTrPs) whose pressure provoked referred pain reproduc-
ing the typical patient's headache, have been described
both in chronic tension type headache [7] and in migraine
[8], indicating that peripheral sensitization may play a
role in the pathophysiology of headache. Also Ashkenazi
and Young reported the occurrence of cutaneous allodinia
in cluster headache, especially prevalent in chronic
patients with a longer duration of the disease, a finding
which suggests that central sensitization may also be
present in this condition [9]. As cluster headache and
migraine share some common features concerning
trigeminovascular system involvement and response to
some abortive and prophylactic drugs, we hypothesized
that first neuron hypersensitivity could be also present in
patients with cluster headache. Also, just at a clinical level,
we noticed that some patients experiencing cluster head-
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ache reported that sometimes their attacks were triggered
by the wind or when combing their hair, data suggesting
the existence of peripheral sensitization.
Based on all the above mentioned data, we decided to
examine patients with cluster headache in order to ascer-
tain if referred pain of cluster characteristics suggestive of
peripheral sensitization could be observed and, if present,
to explore the potential usefulness of anaesthetic injec-
tions on pain management. We present herein the results
of a case series of patients.
Case description
We explored patients suffering from cluster headache
attending our headache pain unit asking for treatment.
Their clinical data were reconsidered to confirm that the
diagnosis was in accordance to the International Head-
ache Society revised criteria [10]. Every patient gave
informed consent to be examined and, when applicable,
injected. In every case an exploration of the scalp and neck
was performed by a physician specifically trained in a pain
clinic in the detection and manipulation of TrPs, and by
means of bilateral finger palpation with a pressure not
exceeding 4 kg (i.e. when the pressure applied provoked
the typical "blanching of nail" of the explorer's finger).
Active trigger points (TrPs) were defined as those areas
whose palpation elicited referred pain which reproduced,
by its location, characteristics, and/or time sequence, the
patient's typical cluster attack. Referred pain of non-clus-
ter characteristics as well as tenderness in the explored
areas, if present, were not taken in account for injection
since we considered that they did probably not reflected
peripheral sensitization due to cluster headache.
In most of the cases, the inactivation of the active myofas-
cial trigger points was done by inserting a needle inside
the taut band of the MTrP and injecting 3% mepivacaine;
after waiting a couple of minutes the exploration was
repeated in order to check if the TrP had been inactivated.
When this was not the case, the injection was repeated as
necessary up to a maximum of 1 ml of drug en each MTrP,
some of them requiring up to 4–5 injections during the
same session. However, some muscles – as it is the case of
the external pterigoideus -are almost impossible to
explore directly due to their location; in this case the
exploration was done, according to the well-known dia-
grams of Simons et al [11], examining the zone of influ-
ence this muscle over the skin and subcutaneous
surrounding areas and injecting at this level.
Injections were done in the following circumstances: a)
when the patient was experiencing a full blown cluster
attack in order to see if the injection was able to stop the
attack (abortive therapy), b) within one and four hours
before the usual time of the attack occurrence in order to
ascertain if it could be prevented (preemptive therapy)
and c) in a regular basis, one to five days weekly depend-
ing on patients' evolution and availability to come to the
pain unit (prophylactic therapy). Conditions a) and b)
were performed in patients whose attacks followed a fairly
regular schedule during the day, appointing them around
the time when an attack was expected to occur. Condition
c) was applied exclusively to those patients suffering
chronic cluster headache; those patients filled a headache
diary in order to control the frequency of the cluster
attacks along the study period.
Twelve male consecutive patients were studied. Their
demographic and clinical characteristics are shown in
Table 1; all of the subjects with chronic cluster headache
were totally refractory to their current prescribed pharma-
cological treatment which are also shown in the table; pre-
vious failed prophylactic drugs included prednisone,
lithium, verapamil, β blockers (propranolol, nadolol),
ergotamine, chlorpromazine, amitriptyline, car-
bamazepine, methysergide, flunarizine, and topiramate.
Table 1: Demographic and clinical data of patients
Patient Sex Age Diagnosis
(location)
Illness duration
(years)
Attacks' frequency
(daily)
Current prophylactic drugs
1 M 45 episodic (R) 20 1–2 ------
2 M 39 episodic (L) 21 1 ------
3 M 40 episodic (A) 12 3–4 ------
4 M 51 episodic (R) 12 2 ------
5 M 43 chronic (A) 13 1–2 verapamil
6 M 48 chronic (A) 21 3–4 valproate
7 M 47 chronic (L) 10 1–4 verapamil + lithium
8 M 36 chronic (A) 16 5–6 verapamil+gabapentin+baclofen
9 M 33 chronic (R) 25 3–4 daily zolmitriptan
10 M 31 chronic (R) 4 4 verapamil+lithium+valproate
11 M 46 chronic (L) 2 2 verapamil
12 M 38 chronic (L) 6 1–2 prednisone
R: right side; L: left side; A: alternating one side and otherHead & Face Medicine 2008, 4:32 http://www.head-face-med.com/content/4/1/32
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In most of of the cases, the mean duration of the attacks
was of two to three hours, although some of them were
shorter. None of the patients suffered any other chronic
nor severe medical associated condition. Every patient
showed at least one active TrP eliciting referred pain of
cluster characteristics (Table 2). Thirteen (28.9%) of them
were found in temporalis muscle, 8 (17.8%) in external
pterygoideus muscle, 5 (11.1%) in suboccipital area, the
remaining ones being disseminated in different heteroge-
neous areas. In 9 (75%) patients the location of active
TrPs was consistent with pain laterality; however, in three
cases, this correlation failed: two patients suffering right
side cluster headache had bilateral active TrPs and one
patient with bilateral alternating cluster attacks had active
TrPs located exclusively on the left side.
As it is shown in Table 2, in 6 patients we could perform
an anaesthetic injection just at the beginning of the attack
and in 5 (85%) of them the cluster was aborted in a period
of time which varied from patient to patient but never
exceeded 15 minutes in the most refractory cases. Also, in
7 patients we were able to perform a preemptive injection
and in 6 (86%) of them the attack was prevented. The use
of anaesthetic injections associated to prophylactic drug
treatment in the eight chronic cluster headache patients,
was shown to reduce attacks' frequency in at least 50%
from their baseline status, in 7 (88%) of them and, in
most of the cases, the severity of the attacks, as well as
their usual duration, were also decreased. In two patients,
the partial improvement observed with needling was sub-
stantially increased after changing the prescribed prophy-
lactic drug.
No patient reported relevant side effects related with injec-
tions. Pain at injection site was reported by one patient,
and rebound headache following injection was reported
by four patients.
Discussion and evaluation
The cases we have presented were not selected from a
broader sample, but were the first consecutive cluster
patients who we had the opportunity to observe. Unex-
pectedly, active trigger points were found in every subject
examined. It seems, therefore, that peripheral sensitiza-
tion can be a non infrequent associated feature in cluster
headache, at least in those patients whose attacks are not
easily controlled.
Myofascial pain is believed to play a relevant role in the
pathogenesis of tension-type headache and the presence
of active MTrPs related with headache severity and dura-
tion has been described in chronic tension-type headache
patients [7]. In migraine patients, where pain is essentially
related with the activation of the trigeminovascular sys-
tem, active MTrPs have also been found [8,12] and their
inactivation by means of repeated anaesthetic injections
has been shown to decrease the frequency and severity of
attacks in patients experiencing severe and treatment-
refractory migraine [13]. To our knowledge, however, the
possibility that active MTrPs could also been found in
cluster headache has not been previously investigated.
Nevertheless, we believe that the mechanism underlying
the presence of active TrPs in each of these primary head-
aches is similar: chronic pain or repeated acute pain sensi-
tize muscular nociceptors creating active TrPs which, in
turn, contribute to potentiate headache pain. This kind of
vicious cycle explains why the number of active MTrPs has
been found to be higher in patients with chronic primary
headaches than in healthy subjects or in patients experi-
encing less frequent headache attacks [7,8].
Table 2: Number of trigger points and results of anaesthetic trigger points injections
Patient Number and location of 
TrPs*
Abortive injection Preemptive injection Prophylactic injection: mean 
decrease in attacks' frequency
# of injections/time (months)
1 1: (R) T N/D effective ------ 3
2 2: (L) P, T effective N/D ------ 6
3 4: (B) B, EP effective effective ------ 10
4 2: (R) SO, T N/D N/D ------ 3
5 4: (B) SO, T N/D N/D 50% 24/7
6 6: (B), EP, M, T N/D N/D 100%** 12/3
7 9: (L) A, EP, F, P, R, ST, S, T effective effective 100% 32/8
8 5: EP, M, P, SD, T N/D not effective no change 24/6
9 3: (L) SD, (B)T not effective effective 50% 17/4
10 4: (B) SO, T N/D N/D 90%** 24/3
11 1: (L) EP effective effective 100% 14/1
12 4: (L) EP, F, N, P, T effective effective 90% 14/1
*: A angular, B buccinator, EP external pterygoideus, F frontalis, M masseter, N nasalis, P procerus, R rhomboid, S sternocleidomastoid, SD superior 
digastric, SO suboccipital group, ST superior trapezius; T temporalis; letters between parenthesis indicate laterality. N/D: not done; **: required a 
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Needling therapies are a widely accepted method in myo-
fascial trigger points management, although the basis of
its potential effectiveness has not been fully clarified
[14,15]. In the treatment of migraine, injection of tender
areas during the attack with either lidocaine or saline was
shown to subside the pain [16], and the prophylactic use
of anaesthetic injections, as mentioned above, was shown
to contribute to patients' improvement [13]. In relation to
cluster headache, several uncommonly used therapeutic
alternatives may, at least in part, act by provoking a first
neuron afferent blockade; this would be the case of great
occipital nerve blockade, great occipital nerve stimula-
tion, sympathetic C7 anaesthetic blockade, and intranasal
lidocaine or cocaine administration [17-21]. Our data,
although uncontrolled, suggest that active TrPs injections
can be also highly effective in cluster attacks management,
either as abortive or as preemptive therapy, and may be of
help in chronic cluster management. As it is estimated that
between 10–20% of cluster patients are refractory to treat-
ment or develop resistance to it [1], the potential role of
active TrP blockade should not be underestimated. Trigger
points injection is an easy to perform and well tolerated
therapy, its main drawback being that it is rarely wholly
effective as monotherapy [22]. The combination of active
TrPs inactivation with prophylactic drug treatment in the
treatment of refractory cluster headache remains a thera-
peutic option worthy to be investigated.
Conclusion
This was just a preliminary and uncontrolled research
and, as such, our results should taken with caution. Also,
it must be stated that all of the patients attending our pain
clinic have been previously diagnosed and treated by
other physicians, so that the sample may be not represent-
ative of the average cluster headache patient. With these
limitations in mind, we think that our data indicate that
first neuron hypersensitivity can be present in cluster
headache and that active trigger points inactivation can be
a useful complementary therapy.
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